Q Biomed Inc.
501 Madison Ave, 14th Floor
81 articles with Q Biomed Inc.
Several International Market Authorisations Expected in Q4 Expanding Access to South and Central America and Asia
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program
Proof of concept would validate platform for multiple indications and therapeutic alternatives in infectious diseases and others
Q Biomed to Scale up Production of Uttroside-B, a Novel Chemotherapeutic for Liver Cancer, in Preparation for IND Filing
Q BioMed continues its collaboration with Chemveda Life Sciences to prepare for pre-clinical evaluation, Orphan Drug filing and Investigational New Drug (IND) filing of Uttroside-B Novel Therapeutic Shows Remarkable Efficacy in HepG2 Cell Lines NEW YORK , July 22, 2020 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very pleased to contin
Q BioMed, Inc. CEO Discusses Recently Announced Global Distribution Partnership with Caligor Coghlan Pharma Services in Audio Interview with SmallCapVoice.com
SmallCapVoice.com, Inc. (“SCV”) today announces the availability of a new interview with Q BioMed Inc. (“the Company”) (OTCQB: QBIO), a commercial stage biotech company, CEO Denis Corin, who discusses the development of the Company’s exclusive Named Patient Program distribution agreement for its non-opioid metastatic cancer bone pain drug, Strontium89, with Caligor Coghlan Pharma Services (CCPS) for the ex-U.S. market
Q BioMed Announces Global Distribution Partnership With Caligor Coghlan Pharma Services for its Non-Opioid Cancer Palliation Drug
Caligor Coghlan Pharma Services to Distribute Strontium89 (Strontium Chloride Injection Sr-89 USP) Outside the United States Agreement opens international markets ahead of schedule under Named Patient Program
- Strontium89 launched; contract manufacturer now producing commercial scale quantities; sales revenue expected to be booked this quarter - $25 million in annual sales anticipated in 2022 based on the current potential market size - COVID-19 Investigational New Drug application (or similar clinical trial proposal) to regulators planned for late 2020 [30-June-2020]
QBioMed to Support and Exhibit at Living Beyond Breast Cancer 2020 Virtual Conference on June 13-14, 2020
Q BioMed (OTC: QBIO) is proud to be a Supporter of the Living Beyond Breast Cancer (LBBC) 2020 Virtual Conference on Metastatic Breast Cancer taking place June 13 and 14, 2020.
Q BioMed Launches New Website Strontium89.com and Digital Marketing Campaign for Strontium89 (Strontium Chloride Sr-89 Injection, USP) Non-opioid Treatment for Metastatic Bone Pain
- Campaign for doctors and healthcare professionals eliminates need for in-person sales rep meetings; ideally suited for current social distancing guidelines and unique challenges faced by healthcare professionals today - Several institutions considering use of Strontium89 for their patients [15-May-2020] NEW YORK , May 15, 2020 /PRNewswire/ -- Q BioMed In
Artificial Intelligence (AI) and computational biophysics will be deployed to rapidly develop drugs for COVID-19 and other viral infections based on Mannin Research's Tie2 platform in new joint venture with Cyclica
Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a Minimum of $3,800,000 of Debt Conversion
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the entering of a significant financial transaction with its lead investor, Yorkville Advisors Global ("YA").
4/3/2020Companies strengthen their leadership teams and executive boards with this week's Movers & Shakers.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the appointment of Geoff Fatzinger as the Global Head of Regulatory Affairs
Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today the appointment of Kristin Keller to the newly created position of Chief Commercial Officer. Kristin will be focused on driving the global
- First orders for product received, with initial doses to ship in February - Full commercial production and availability starting in March
Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and Other Infectious Diseases
- Preclinical data show unique platform addresses vascular leakage, which may support the health of patients during coronavirus infection
Q BioMed Technology Partner Mannin Research Inc. Presents Data Showing Potential Treatment to Protect the Kidney in Acute Kidney Injury Using Mannin Tie2 Activator
Data presented during "Acute Kidney Injury" symposium at the American Society for Nephrology 2019 Annual Meeting Expands Pipeline of Platform Technology
Q BioMed Inc. (OTCQB: QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture the Company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony
Q BioMed Announces Commercial Partnership With Jubilant Radiopharma for the Distribution of its Non-Opioid Cancer Palliation Drug in the United States
Jubilant Radiopharma to Distribute Strontium-89 Chloride Injection USP Throughout the United States
Under terms of the global royalty agreement, Q BioMed will assume immediate ownership of the pain asset, as well as an abbreviated new drug application for the treatment.